Corbus Pharmaceuticals(CRBP) Newsfilter·2025-03-28 12:00Core Insights - Corbus Pharmaceuticals has initiated the dosing of the first subject in the Phase 1 trial of CRB-913, a drug aimed at treating obesity, under an open IND in the United States [1][4] - CRB-913 is a second-generation cannabinoid type-1 (CB1) receptor inverse agonist, designed to induce weight loss with a focus on minimizing neuropsychiatric risks associated with earlier drugs in this class [2][9] - Pre-clinical data indicates that CRB-913 is significantly more peripherally restricted compared to both monlunabant and rimonabant, with a brain-to-plasma ratio fifty times lower than rimonabant [3][9] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio that includes CRB-701, an antibody drug conjugate, and CRB-601, an anti-integrin monoclonal antibody [6] - The company aims to address unmet medical needs in weight loss through innovative mechanisms, including potential uses of CRB-913 as monotherapy or in combination with other therapies [5][9] Clinical Development Timeline - The SAD/MAD portion of the Phase 1 trial is expected to be completed in Q3 2025, followed by a Phase 1b dose-range finding study set to commence in Q4 2025 and conclude in the second half of 2026 [4][9]